Discover the latest OIG Advisory Opinion clarifying cancer detection practices and compliance. Learn valuable insights for healthcare companies on regulatory navigation.

Explore the complex insurance challenges surrounding high-cost cancer treatments like Keytruda and the legal battles patients face to access essential medications.

Explore the evolving landscape of cancer care costs and insurance regulations, revealing financial challenges in treatment access and the role of federal policies.

Discover how the new Oncology Care Model improves cancer care and enhances Medicare services through value-based approaches and quality-focused initiatives.

Discover the 2026 Harold M. Weintraub Award recipients announced by Fred Hutch Cancer Center, celebrating outstanding contributions to biological sciences.

Explore how recent advancements in cancer care impact the insurance industry, focusing on CAR T-cell therapy and regulatory compliance.

Explore the complexities of prior authorizations in health insurance, emphasizing coordination among providers and the need for timely updates in medical guidelines.

Explore the challenges of patient enrollment in cancer clinical trials and how insurance reforms can improve accessibility for those in need.

CMS announces a 9.7% increase in Medicare Part B premiums for 2026, affecting individuals earning $109,000 or less. Updates on oncology drug reimbursement and legal challenges to the CMS 340B drug rebate pilot program highlight shifting dynamics in Medicare regulation and healthcare compliance.

In 2025, Medicare Part D caps oral cancer drug out-of-pocket costs at $2,000, introducing a monthly payment plan to aid affordability and adherence for beneficiaries.